Abstract

BackgroundAltered DNA methylation patterns play important roles in cancer development and progression. We examined whether expression levels of genes directly or indirectly involved in DNA methylation and demethylation may be associated with response of cancer cell lines to chemotherapy treatment with a variety of antitumor agents.ResultsWe analyzed 72 genes encoding epigenetic factors directly or indirectly involved in DNA methylation and demethylation processes. We examined association of their pretreatment expression levels with methylation beta-values of individual DNA methylation probes, DNA methylation averaged within gene regions, and average epigenome-wide methylation levels. We analyzed data from 645 cancer cell lines and 23 cancer types from the Cancer Cell Line Encyclopedia and Genomics of Drug Sensitivity in Cancer datasets. We observed numerous correlations between expression of genes encoding epigenetic factors and response to chemotherapeutic agents. Expression of genes encoding a variety of epigenetic factors, including KDM2B, DNMT1, EHMT2, SETDB1, EZH2, APOBEC3G, and other genes, was correlated with response to multiple agents. DNA methylation of numerous target probes and gene regions was associated with expression of multiple genes encoding epigenetic factors, underscoring complex regulation of epigenome methylation by multiple intersecting molecular pathways. The genes whose expression was associated with methylation of multiple epigenome targets encode DNA methyltransferases, TET DNA methylcytosine dioxygenases, the methylated DNA-binding protein ZBTB38, KDM2B, SETDB1, and other molecular factors which are involved in diverse epigenetic processes affecting DNA methylation. While baseline DNA methylation of numerous epigenome targets was correlated with cell line response to antitumor agents, the complex relationships between the overlapping effects of each epigenetic factor on methylation of specific targets and the importance of such influences in tumor response to individual agents require further investigation.ConclusionsExpression of multiple genes encoding epigenetic factors is associated with drug response and with DNA methylation of numerous epigenome targets that may affect response to therapeutic agents. Our findings suggest complex and interconnected pathways regulating DNA methylation in the epigenome, which may both directly and indirectly affect response to chemotherapy.

Highlights

  • Altered DNA methylation patterns play important roles in cancer development and progression

  • Drug response data To examine the relationship between pretreatment Gene affecting DNA methylation or demethylation (GMD) expression and tumor response to antitumor agents, we used gene expression, DNA methylation, and drug response data for 645 cell lines, the identity of which was matched between the Cancer Cell Line Encyclopedia and the Genomics of Drug Sensitivity in Cancer datasets [67,68,69,70,71,72] (Additional file 2: Table S2)

  • In the CellminerCDB analysis of NCI-60 cell line panel data, we examined Pearson correlation between GMD expression and log (GI50) measures of drug response [48, 94]

Read more

Summary

Introduction

Altered DNA methylation patterns play important roles in cancer development and progression. We examined whether expression levels of genes directly or indirectly involved in DNA methylation and demethylation may be associated with response of cancer cell lines to chemotherapy treatment with a variety of antitumor agents. Cancer cells acquire multiple epigenomic alterations, including aberrant DNA methylation and DNA hydroxymethylation of genes and genome regions, loss or gain of imprinting and allele switching of imprinted loci, and global DNA hypomethylation [1,2,3,4,5,6]. Many epigenetic factors directly or indirectly dynamically influence genome region-specific or global DNA methylation in the germ line, embryonic, or somatic adult cells (Additional file 1: Table S1). A molecular complex containing AID, TDG, and GADD45A participates in DNA demethylation via the BER pathway [20]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call